Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carol Zhao

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Journal of the Endocrine Society|March 27, 2025
Long-Acting Growth Hormone for Pediatric Growth Hormone DeficiencyNorbert Albers, Sarah Cadarette, Ben Feakins, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|April 15, 2018
Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEALHarrison W Farber, David B Badesch, Raymond L Benza, et al.
Chest|January 23, 2018
Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL RegistryRobert P Frantz, Harrison W Farber, David B Badesch, et al.
Chest|November 10, 2018
ResponseRobert P Frantz, Carol Zhao, Harrison W Farber, et al.
Springerplus|July 22, 2016
Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trialJavier Cortés, Hope S Rugo, Chris Twelves, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 28, 2017
Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysisMurali M Chakinala, Daniel W Coyne, Raymond L Benza, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|August 22, 2025
Early US Real-World Treatment Patterns and Outcomes in Palopegteriparatide Treatment for Patients with HypoparathyroidismTimothy Graham, Dolores M Shoback, Lisa Abbott, et al.
JHLT Open|March 27, 2025
Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertensionRichard Channick, Sarah Medrek, Marion Delcroix, et al.
The European Respiratory Journal|May 6, 2020
Risk stratification in pulmonary arterial hypertension using Bayesian analysisManreet K Kanwar, Mardi Gomberg-Maitland, Marius Hoeper, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 4, 2026
Palopegteriparatide for Adults with Chronic Hypoparathyroidism: Skeletal Dynamics Through 3 yr of the Phase 2 paTH Forward TrialMishaela R Rubin, Bart L Clarke, Lorenz C Hofbauer, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Journal of the Endocrine Society|March 27, 2025
Long-Acting Growth Hormone for Pediatric Growth Hormone DeficiencyNorbert Albers, Sarah Cadarette, Ben Feakins, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|April 15, 2018
Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEALHarrison W Farber, David B Badesch, Raymond L Benza, et al.
Chest|January 23, 2018
Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL RegistryRobert P Frantz, Harrison W Farber, David B Badesch, et al.
Chest|November 10, 2018
ResponseRobert P Frantz, Carol Zhao, Harrison W Farber, et al.
Springerplus|July 22, 2016
Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trialJavier Cortés, Hope S Rugo, Chris Twelves, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 28, 2017
Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysisMurali M Chakinala, Daniel W Coyne, Raymond L Benza, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|August 22, 2025
Early US Real-World Treatment Patterns and Outcomes in Palopegteriparatide Treatment for Patients with HypoparathyroidismTimothy Graham, Dolores M Shoback, Lisa Abbott, et al.
JHLT Open|March 27, 2025
Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertensionRichard Channick, Sarah Medrek, Marion Delcroix, et al.
The European Respiratory Journal|May 6, 2020
Risk stratification in pulmonary arterial hypertension using Bayesian analysisManreet K Kanwar, Mardi Gomberg-Maitland, Marius Hoeper, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 4, 2026
Palopegteriparatide for Adults with Chronic Hypoparathyroidism: Skeletal Dynamics Through 3 yr of the Phase 2 paTH Forward TrialMishaela R Rubin, Bart L Clarke, Lorenz C Hofbauer, et al.
Pageof 4